Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK14 | O94921 | 12/20 | 0.49 |
| ▸ | CCNY | Q8ND76 | 11/20 | 0.49 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2031219 | 0.95 | CDK14 (0.51) | CDK14CCNYCCNT1CDK9CDK5 | |
| SCHEMBL8262598 | 0.92 | CDK14 (0.46) | CDK14CCNYCCNT1CDK9CDK5 | |
| SCHEMBL8261496 | 0.92 | CDK14 (0.46) | CDK14CCNYCCNT1CDK9CDK5 | |
| SCHEMBL13993668 | 0.91 | CDK14 (0.46) | CDK14CCNYCCNT1CDK9CDK5 | |
| SCHEMBL5007794 | 0.91 | CDK14 (0.47) | CDK14CCNY | |
| SCHEMBL8262073 | 0.90 | CDK14 (0.47) | CDK14CCNYCCNT1CDK9CDK5 | |
| SCHEMBL13993684 | 0.89 | CDK14 (0.45) | CDK14CCNY | |
| SCHEMBL13993667 | 0.89 | CDK14 (0.46) | CDK14CCNYCCNT1CDK9CDK5 | |
| SCHEMBL8263071 | 0.89 | CDK14 (0.44) | CDK14CCNYCCNT1CDK9CDK5 | |
| SCHEMBL13993657 | 0.89 | CDK14 (0.44) | CDK14CCNYCCNT1CDK9CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| US-20090318430-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318430-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090142337-A1 | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment | ASTEX THERAPEUTICS LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| US-20090142337-A1 | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment | ASTEX THERAPEUTICS LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| US-20080139620-A1 | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| US-20080139620-A1 | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318430-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | CDK1, CCNO, CDK14 | CDK14 3/4885CCNY 17/4885SLC6A9 3840/4885 |
| US-20080139620-A1 | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's | CDK1, CDK3, CDK2 | CDK14 18/4885CCNY 53/4885SLC6A9 4192/4885 |
| US-20090142337-A1 | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment | CDK1, CDK4, CDK3 | CDK14 18/4885CCNY 48/4885SLC6A9 3610/4885 |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | SLC10A1, CYP11B2, SDHB | CDK14 1723/4885CCNY 748/4885SLC6A9 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.